ArticleNeurosurgery practice2026
Particle Embolization of the Middle Meningeal Artery for Subdural Hematoma: Efficacy and Cost Considerations.
Article in Neurosurgery practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSubdural hematoma (SDH) is an increasingly common pathology. Middle meningeal artery embolization (MMAE) is an endovascular procedure shown to be efficacious in treating chronic subdural hematoma. This study aims to explore the efficacy of MMAE using polyethylene vinyl (PVA) particle and highlight cost effectiveness.
methodsA single-center retrospective review was conducted. Patients who underwent MMAE from 2020 to 2022 were included. Demographics, medical history, symptoms on presentation, procedural details, and radiographic variables were collected. Rescue surgical evacuation and decreased SDH thickness by 50% were the primary end points.
resultsFifty-nine patients were included, with 43 male and 16 female patients, with an average age of 72.9 ± 9.6 years. Preprocedure SDH thickness was 14.7 ± 6.2 mm and midline shift was 6.2 ± 4.5 mm. Thirty-one patients (52.5%) were on home antiplatelet medications; 19 patients (32.3%) were on anticoagulants. PVA particles were the only embolisate used. Three patients underwent general anesthesia, and monitored anesthesia care was utilized for the rest. Postprocedurally, 4 patients required rescue surgical intervention (6.8%). Fifty-four (91.5%) patients had a decrease in SDH size by at least 50% at the last follow up visit. No patients had neurological deterioration postprocedurally.
conclusionThis study suggests PVA for primary treatment of chronic subdural hematoma is safe and effective. The cost of 45-150 micron PVA particles is $153, compared with a vial of Onyx, which is $3334. Large-scale trials comparing embolic agents are necessary to assess for efficacy and safety in the setting of cost differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.